| 18.33 -3.195 (-14.84%) | 06-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.05  |
1-year : | 34.95 |
| Resists | First : | 24.87 |
Second : | 29.93 |
| Pivot price | 22.68 |
|||
| Supports | First : | 16.69 |
Second : | 13.89 |
| MAs | MA(5) : | 22 |
MA(20) : | 23.62 |
| MA(100) : | 25.16 |
MA(250) : | 17.78  |
|
| MACD | MACD : | -1.1 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 21.6 |
D(3) : | 26 |
| RSI | RSI(14): 30.4 |
|||
| 52-week | High : | 34.09 | Low : | 7.78 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GLSI ] has closed below the lower bollinger band by 26.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 24.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.34 - 22.53 | 22.53 - 22.65 |
| Low: | 16.41 - 16.56 | 16.56 - 16.66 |
| Close: | 18.11 - 18.37 | 18.37 - 18.54 |
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
Thu, 25 Jun 2026
Enterprise value to EBIT forward of Greenwich LifeSciences, Inc. – NASDAQ:GLSI - TradingView
Thu, 25 Jun 2026
Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Wed, 03 Jun 2026
Greenwich LifeSciences (GLSI) loss widens as ATM equity raises fund trials - Stock Titan
Mon, 01 Jun 2026
Breast cancer trial: GLSI-100 shots spark injection-site reactions over time - Stock Titan
Mon, 01 Jun 2026
GREENWICH LIFESCIENCES ($GLSI) Releases Q4 2025 Earnings | GLSI Stock News - Quiver Quantitative
Mon, 01 Jun 2026
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026 - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 47.8 (%) |
| Held by Institutions | 12.4 (%) |
| Shares Short | 1,520 (K) |
| Shares Short P.Month | 1,540 (K) |
| EPS | -1.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.36 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -211.3 % |
| Return on Equity (ttm) | -676.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -11.39 |
| PEG Ratio | 0 |
| Price to Book value | 50.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -21.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|